Associate Professor/Division Chief, Washington University School of Medicine in St. Louis
Ebony B. Carter, MD, MPH
What is your presentation about?
We will explore the data supporting one- vs. two-step testing for gestational diabetes. This presentation aims to answer the question, “Is the significant increase in gestational diabetes diagnosis and treatment associated with one-step testing justified by improved maternal and neonatal outcomes?”
What makes this topic important in 2022?
The optimal screening strategy with one- or two-step testing for gestational diabetes (GDM) is controversial, but recently published randomized controlled trials (RCTs) may inform the best approach.
How did you become involved with this area of diabetes research or care?
As a high-risk obstetrician studying gestational diabetes, the heterogeneity in diagnostic strategies makes comparisons across study samples difficult. We all have a vested interest in determining the optimal testing strategy to minimize maternal and neonatal morbidity and mortality.
What are you most looking forward to at the 82nd Scientific Sessions?
I look forward to seeing old friends and colleagues, meeting new ones, and learning about the latest science in diabetes and pregnancy.